Romosozumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Romosozumab and local guidelines before prescribing.

Anabolic bone agent

Mechanism

Sclerostin monoclonal antibody (anabolic).

Uses

Severe osteoporosis at high fracture risk.

Dosing

Side effects

Hypocalcaemia, arthralgia, injection-site reaction; MI and stroke risk.

Interactions

Few.

Contraindications and cautions

Prior MI or stroke, hypocalcaemia

Monitoring

Calcium, cardiovascular risk

Pregnancy and breastfeeding

Not for use

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Contraindicated after MI or stroke in the last year; follow with antiresorptive therapy.

More from the textbook: uses, cautions and other points
Where it is discussed in the book